Clinical Trial Detail

NCT ID NCT02282020
Title Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

fallopian tube cancer

peritoneum cancer

ovary serous adenocarcinoma

endometrioid ovary carcinoma

Therapies

Topotecan

Paclitaxel

Pegylated liposomal-doxorubicin

Gemcitabine

Olaparib

Age Groups: child adult senior

No variant requirements are available.